Cannabis Clinical Trials

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused… read more at: https://www.newcannabisventures.com/gw-pharma-reports-success-in-brain-cancer-phase-2-clinical-trial/

by

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused… read more at: https://www.newcannabisventures.com/gw-pharma-reports-success-in-brain-cancer-phase-2-clinical-trial/

by

The Ministerial Committee for Legislation gave an initial nod on Sunday for the export of medical cannabis in what could be a windfall for companies in Israel, widely regarded as a leader in research in the field. The initiator of the bill, MK Yoav Kisch (Likud), said the approval of his legislation could boost the […]

by

NANAIMO, British Columbia–(BUSINESS WIRE)– Tilray, a global leader in medical cannabis research and production, today announced that it has received necessary regulatory approvals in Canada and Chile to export medical cannabis for distribution to Chilean patients. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170201005120/en/ “Today’s announcement marks Tilray’s entry into Latin […]

by

The Initial Focus Will Be Clinical Studies of the Company’s Prana Product Line DENVER, CO / ACCESSWIRE / January 30, 2017 / United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) today announced that it, along with its Jamaica-based subsidiary, Cannabis Research Development (“CRD”), has signed a Letter of Intent (the “LOI”) with the Caribbean […]

by

OTTAWA, ONTARIO–(Marketwired – Jan 23, 2017) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP)(TBP.CN) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase […]

by

Privacy Legal Policy This website is part of the Investing News Network published by Dig Media Inc. Overview Contact Information Information Collected Ad Server Information Use Remarketing Future Use Accessing Your Data Security Your Acceptance of These Terms Overview INN’s mission is to be the world’s number one source of independent, unbiased news and education […]

by

OTTAWA, ONTARIO–(Marketwired – Jan. 23, 2017) – PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP)(CSE:TBP.CN) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase […]

by

Gilles Richard doesn’t harbour any illusions about his disease. It has latched itself to his lungs, his bones and he fears it will eventually seep its way into his brain. Over time, he says, the sickness will prevail. “I like to say I just want five good years,” says Richard, a retired physicist. “But it could be […]

by

SAN DIEGO, Jan. 19, 2017 /PRNewswire/ — Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has entered clinical trials at Wageningen University in the Netherlands for treatment of irritable bowel syndrome (IBS) with AXIM’s CanChew Plus® cannabidiol […]

by

NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum at Wageningen University in the Netherlands.   The research team previously received approval from the Medical […]

by